InsidersTradesSigma
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
无可用的信号评分。
Discover the complete record of transactions filed by Reich Siegfried, Vice-Président Exécutif. Director active across 1 company, notably Turning Point Therapeutics, Inc.. Aggregated, 1 reports have been published. Breakdown: 0 buy · 1 sell. Total volume traded: €13k. Activity tracked since 9 February 2022. The latest transaction was disclosed on 9 February 2022 (Cession). Regulator: SEC (Form 4). The full history is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 条申报中的 1 条
Reich Siegfried is Executive Vice President and Chief Scientific Officer at Turning Point Therapeutics, Inc. In this role, he oversees the company's research and development initiatives focused on innovation in oncology treatments. His scientific expertise and strategic vision are essential for the company's success. Reich is committed to advancing Turning Point's mission by developing targeted therapies for patients.